Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Purchased by IFM Investors Pty Ltd

IFM Investors Pty Ltd raised its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 12.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,074 shares of the medical equipment provider’s stock after buying an additional 1,924 shares during the period. IFM Investors Pty Ltd’s holdings in Zimmer Biomet were worth $2,324,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. State Street Corp boosted its position in Zimmer Biomet by 0.5% during the first quarter. State Street Corp now owns 8,542,497 shares of the medical equipment provider’s stock worth $865,503,000 after purchasing an additional 42,671 shares during the period. Nordea Investment Management AB grew its holdings in shares of Zimmer Biomet by 90.5% during the second quarter. Nordea Investment Management AB now owns 6,083,680 shares of the medical equipment provider’s stock worth $708,140,000 after purchasing an additional 2,890,589 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Zimmer Biomet by 2.5% during the second quarter. Bank of New York Mellon Corp now owns 1,935,002 shares of the medical equipment provider’s stock worth $230,961,000 after purchasing an additional 47,818 shares during the last quarter. Waddell & Reed Financial Inc. grew its holdings in shares of Zimmer Biomet by 9.6% during the first quarter. Waddell & Reed Financial Inc. now owns 1,662,226 shares of the medical equipment provider’s stock worth $168,018,000 after purchasing an additional 145,934 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Zimmer Biomet by 9.3% during the second quarter. Charles Schwab Investment Management Inc. now owns 1,060,638 shares of the medical equipment provider’s stock worth $126,598,000 after purchasing an additional 90,062 shares during the last quarter. 87.17% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Zimmer Biomet stock traded down $0.61 during trading on Friday, reaching $146.93. 770,258 shares of the company’s stock were exchanged, compared to its average volume of 1,448,678. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.02 and a current ratio of 2.18. Zimmer Biomet Holdings, Inc. has a 1-year low of $74.37 and a 1-year high of $161.11. The company has a market cap of $30.42 billion, a P/E ratio of 918.37, a PEG ratio of 4.31 and a beta of 1.37. The firm’s 50-day moving average price is $140.33 and its 200 day moving average price is $127.53.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, August 4th. The medical equipment provider reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.77. Zimmer Biomet had a return on equity of 10.07% and a net margin of 0.52%. The company had revenue of $1.23 billion during the quarter, compared to analysts’ expectations of $922.16 million. During the same quarter in the previous year, the firm earned $1.93 EPS. Zimmer Biomet’s revenue was down 38.4% on a year-over-year basis. As a group, equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 4.71 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.24 per share. The ex-dividend date is Tuesday, September 29th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.65%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 12.20%.

Several analysts have recently commented on the company. Argus increased their target price on Zimmer Biomet from $145.00 to $160.00 in a report on Friday, September 4th. Needham & Company LLC began coverage on Zimmer Biomet in a report on Tuesday, August 4th. They issued a “strong-buy” rating and a $162.00 price target on the stock. Credit Suisse Group reiterated a “sell” rating and issued a $99.00 price target on shares of Zimmer Biomet in a report on Wednesday, August 5th. Wolfe Research began coverage on Zimmer Biomet in a report on Friday, September 11th. They issued an “outperform” rating and a $174.00 price target on the stock. Finally, Raymond James raised their price target on Zimmer Biomet from $150.00 to $170.00 and gave the company a “strong-buy” rating in a report on Monday, October 12th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $152.96.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Read More: Pattern Day Trader – What is the PDT Rule?

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.